Paediatric patients at risk for glucocorticoid-induced osteoporosis benefit from treatment with alendronic acid

Author：

ISSN： 0114-9954

Source： Reactions Weekly, Vol.1, Iss.1182, 2007-01, pp. : 4-4

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pathogenesis and Treatment of Glucocorticoid-Induced Osteoporosis

By Rackoff P.J.

Drugs & Aging, Vol. 12, Iss. 6, 1998-06 ,pp. : 477-484

Adis International

Access to resources Recommend Favorite

The prevention and treatment of glucocorticoid-induced osteoporosis in clinical practice

By Walker-Bone Karen Wood Angela Hull Richard Ledingham Joanna M McCrae Fiona C Shaban Ragai Thomas Alastair Mackay Kirsten

Clinical Medicine, Vol. 4, Iss. 5, 2004-09 ,pp. : 431-436

Royal College Of Physicians

Access to resources Recommend Favorite

Prevention of glucocorticoid-induced osteoporosis

By van Brussel MS Bultink IEM Lems WF

Expert Opinion on Pharmacotherapy, Vol. 10, Iss. 6, 2009-04 ,pp. : 997-1005

Informa Healthcare

Access to resources Recommend Favorite

Therapeutic patenting for glucocorticoid-induced osteoporosis

By Cooper M.S. Stewart P.M.

Expert Opinion on Therapeutic Patents, Vol. 10, Iss. 6, 2000-06 ,pp. : 847-857

Informa Healthcare

Access to resources Recommend Favorite

Alendronic acid tops alfacalcidol for steroid-induced osteoporosis

Inpharma, Vol. 1, Iss. 1552, 2006-01 ,pp. : 15-15

Adis International

Access to resources Recommend Favorite